SEC Form 10-K filed by Ocean Biomedical Inc.
$OCEA
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
Strategic diversification into power infrastructure and cryptocurrencies supports long-term biopharma innovation PROVIDENCE, R.I., April 22, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ:OCEA), a biopharmaceutical company focused on pioneering treatments for cancer, infectious diseases, and fibrosis, today announced a strategic expansion of its business operations to include power infrastructure development and a cryptocurrency treasury strategy, including Bitcoin and Solana. This move comes as part of a deliberate plan to strengthen Ocean Biomedical's financial foundation and enhance long-term value creation for shareholders. The Company will leverage its leadership team's exp
PROVIDENCE, R.I., March 28, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ:OCEA), a biopharmaceutical company dedicated to advancing innovative treatments for cancer, infectious diseases, and fibrosis, today announced that the China National Intellectual Property Administration (CNIPA) has granted a notice of grant on patent right for its bispecific antibodies targeting CHI3L1 and PD1, designed to enhance T cell-mediated cytotoxic effects on tumor cells. This newly issued patent will strengthen Ocean Biomedical's intellectual property portfolio and provides protection in one of the world's largest pharmaceutical markets. The granted claims cover the novel design and therapeutic a
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) today announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy candidates to favorably interact with tyrosine kinase inhibitors (TKI), such as osimertinib that are used to treat non-small cell lung cancer (NSCLC). Specifically, they demonstrate that Ocean's immunotherapy candidates provide synergy with the TKI therapies (gefitinib and osimertinib) to suppress tumor growth and progression. In addition, the paper's findings demonstrate that its proprietary cancer immunothe
3 - Ocean Biomedical Holdings, Inc. (0001836612) (Issuer)
8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
10-Q - Ocean Biomedical, Inc. (0001869974) (Filer)